Law360, New York (December 29, 2008, 12:00 AM EST) -- A judge has given preliminary approval to a $65 million settlement that allows Forest Laboratories to end a securities class action that claimed it provided misleading information about the safety of its blockbuster antidepressants Celexa and Lexapro.
In an order Dec. 23, Judge Richard M. Berman of the U.S. District Court for the Southern District of New York tentatively signed off on the deal. He scheduled a final hearing on the matter for April 23 and set a schedule for notification of class members.
Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.